Disease reversibility in patients with post-hepatitis c cirrhosis: Is the point of no return the same before and after liver transplantation? A review

Transplantation

Volumn 101, Issue 5, 2017, Pages 916-923

  Vinaixa, Carmen ^a,b   Strasser, Simone I ^c   Berenguer, Marina ^a,b,d  

^a HOSPITAL UNIVERSITARIO LA FE   (Spain)

^b INSTITUTO DE SALUD CARLOS III   (Spain)

^c ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^d UNIVERSITY OF VALENCIA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; INTERFERON; LEDIPASVIR; PEGINTERFERON; PEGINTERFERON ALPHA2B; RIBAVIRIN; SOFOSBUVIR; VELPATASVIR;

DECOMPENSATED LIVER CIRRHOSIS; HEPATITIS C; HUMAN; INFECTION CONTROL; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; MODEL FOR END STAGE LIVER DISEASE SCORE; MORTALITY RATE; OVERALL SURVIVAL; POSTOPERATIVE PERIOD; PRACTICE GUIDELINE; PREOPERATIVE CARE; REVIEW; SURVIVAL RATE; SUSTAINED VIROLOGIC RESPONSE; TREATMENT CONTRAINDICATION; TREATMENT OUTCOME; TREATMENT RESPONSE; COMPLICATION; DISEASE COURSE; DRUG ADMINISTRATION; HEPATITIS C, CHRONIC; MULTIMODALITY CANCER THERAPY; POSTOPERATIVE CARE; VIROLOGY;

ANTIVIRAL AGENTS; COMBINED MODALITY THERAPY; DISEASE PROGRESSION; DRUG ADMINISTRATION SCHEDULE; HEPATITIS C, CHRONIC; HUMANS; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; POSTOPERATIVE CARE; TREATMENT OUTCOME;

EID: 85008368386     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0000000000001633     Document Type: Review

References (51)

1. Morgan RL, Baack B, Smith BD, et al. Annals of internal medicine review eradication of hepatitis C virus infection and the development of hepatocellular carcinoma. Ann Intern Med. 2013;158:329-337.
2. Simmons B, Saleem J, Heath K, et al. Long-term treatment outcomes of patients infected with hepatitis C virus: a systematic review and metaanalysis of the survival benefit of achieving a sustained virological response. Clin Infect Dis. 2015;61:730-740.
3. van der Meer AJ, Veldt BJ, Feld JJ, et al. Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. JAMA. 2012;308: 2584-2593.
4. Poynard T, Moussalli J, Munteanu M, et al. Slow regression of liver fibrosis presumed by repeated biomarkers after virological cure in patients with chronic hepatitis C. J Hepatol. 2013;59:675-683.
5. Shiratori Y, Imazeki F, Moriyama M, et al. Histologic improvement of fibrosis in patientswith hepatitisC who have sustained response to interferon therapy. Ann Intern Med. 2000;132:517-524.
6. Bunchorntavakul C, Reddy KR. Treat chronic hepatitis C virus infection in decompensated cirrhosis-pre-or post-liver transplantation? the ironic conundrum in the era of effective and well-tolerated therapy. J Viral Hepat. 2016;23:408-418.
7. D'Ambrosio R, Aghemo A, Rumi MG, et al. Amorphometric and immunohistochemical study to assess the benefit of a sustained virological response in hepatitis C virus patients with cirrhosis. Hepatology. 2012;56: 532-543.
8. Everson GT, Balart L, Lee SS, et al. Histological benefits of virological response to peginterferon alfa-2a monotherapy in patients with hepatitis C and advanced fibrosis or compensated cirrhosis. Aliment Pharmacol Ther. 2008;27:542-551.
9. Mallet V, Gilgenkrantz H, Serpaggi J, et al. Brief communication: The relationship of regression of cirrhosis to outcome in chronic hepatitis c. Ann Intern Med. 2008;149:399-403.
10. Poynard T, McHutchison J,Manns M, et al. Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C. Gastroenterology. 2002;122:1303-1313.
11. Mandorfer M, Kozbial K, Schwabl P, et al. Sustained virologic response to interferon-free therapies ameliorates HCV-induced portal hypertension. J Hepatol. 2016;65:692-699.
12. Rincon D, Ripoll C, Lo Iacono O, et al. Antiviral therapy decreases hepatic venous pressure gradient in patients with chronic hepatitis C and advanced fibrosis. Am J Gastroenterol. 2006;101:2269-2274.
13. Roberts S, Gordon A, McLean C, et al. Effect of sustained viral response on hepatic venous pressure gradient in hepatitis C-related cirrhosis. Clin Gastroenterol Hepatol. 2007;5:932-937.
14. Ng V, Saab S. Effects of a sustained virologic response on outcomes of patients with chronic hepatitis. C. Clin Gastroenterol Hepatol. 2011;9: 923-30.
15. Bruno S, Crosignani A, Facciotto C, et al. Sustained virologic response prevents the development of esophageal varices in compensated, Child-Pugh class A hepatitis C virus-induced cirrhosis. A 12-year prospective follow-up study. Hepatology. 2010;51:2069-2076.
16. D'Ambrosio R, Aghemo A, RumiMG, et al. The course of esophageal varices in patients with hepatitis C cirrhosis responding to interferon/ribavirin therapy. Antivir Ther. 2011;16:677-684.
17. Di Marco V, Calvaruso V, Ferraro D, et al. Effects of eradicating hepatitis C Virus infection in patients with cirrhosis differ with stage of portal hypertension. Gastroenterology. 2016;151:130-139.e2.
18. Veldt BJ, Heathcote EJ,Wedemeyer H, et al. Sustained virologic response and clinical outcomes in patients with chronic hepatitis C and advanced fibrosis. Ann Intern Med. 2007;147:677-684.
19. Maylin S,Martinot-Peignoux M, Moucari R, et al. Eradication of hepatitis C virus in patients successfully treated for chronic hepatitis C. Gastroenterology. 2008;135:821-829.
20. Knop V, Hoppe D, Welzel T, et al. Regression of fibrosis and portal hypertension in HCV-associated cirrhosis and sustained virologic response after interferon-free antiviral therapy. J Viral Hepat. 2016;23:994-1002.
21. D'Ambrosio R, Aghemo A, Fraquelli M, et al. The diagnostic accuracy of fibroscan for cirrhosis is influenced by liver morphometry in HCV patients with a sustained virological response. J Hepatol. 2013;59:251-256.
22. Charlton M, Seaberg E, Wiesner R, et al. Predictors of patient and graft survival following liver transplantation for hepatitis C. Hepatology. 1998; 28:823-830.
23. Gane EJ, Portmann BC, Naoumov NV, et al. Long-term outcome of hepatitis C infection after liver transplantation.NEngl J Med. 1996;334:815-820.
24. Berenguer M. Systematic review of the treatment of established recurrent hepatitis C with pegylated interferon in combination with ribavirin. J Hepatol. 2008;49:274-287.
25. BerenguerM, Palau A, Aguilera V, et al. Clinical benefits of antiviral therapy in patients with recurrent hepatitis C following liver transplantation. Am J Transplant. 2008;8:679-687.
26. Bizollon T, Ahmed SN, Radenne S, et al. Long term histological improvement and clearance of intrahepatic hepatitis C virus RNA following sustained response to interferon-ribavirin combination therapy in liver transplanted patients with hepatitis C virus recurrence. Gut. 2003;52:283-287.
27. Carrión JA, Navasa M, García-Retortillo M, et al. Efficacy of antiviral therapy on hepatitis C recurrence after liver transplantation: a randomized controlled study. Gastroenterology. 2007;132:1746-1756.
28. Martini S, Sacco M, Strona S, et al. Impact of viral eradication with sofosbuvir-based therapy on the outcome of post-transplant hepatitis C with severe fibrosis. Liver Int. 2017;37:62-70.
29. Iacobellis A, Perri F, Valvano MR, et al. Long-term outcome after antiviral therapy of patientswith hepatitis C virus infection and decompensated cirrhosis. Clin Gastroenterol Hepatol. 2011;9:249-253.
30. Charlton M, Everson GT, Flamm SL, et al. Ledipasvir and sofosbuvir plus ribavirin for treatment of HCV infection in patients with advanced liver disease. Gastroenterology. 2015;149:649-659.
31. Manns M, Samuel D, Gane EJ, et al. Ledipasvir and sofosbuvir plus ribavirin in patients with genotype 1 or 4 hepatitis C virus infection and advanced liver disease: a multicentre, open-label, randomised, phase 2 trial. Lancet Infect Dis. 2016;16:685-697.
32. Poordad F, Schiff ER, Vierling JM, et al. Daclatasvir with sofosbuvir and ribavirin for hepatitis C virus infection with advanced cirrhosis or post-liver transplantation recurrence. Hepatology. 2016;63:1493-1505.
33. CurryMP, O'Leary JG, Bzowej N, et al. Sofosbuvir and velpatasvir for HCV in patients with decompensated cirrhosis.NEnglJMed. 2015;373:2618-28.
34. Cheung MCM, Walker AJ, Hudson BE, et al. Outcomes after successful direct-acting antiviral therapy for patients with chronic hepatitis C and decompensated cirrhosis. J Hepatol. 2016;65:741-747.
35. Foster GR, Irving WL, Cheung MCM, et al. Impact of direct acting antiviral therapy in patients with chronic hepatitis C and decompensated cirrhosis. J Hepatol. 2016;64:1224-1231.
36. Afdhal N, Asselah T, EversonGT, et al. HCVeradication results in reduction of hepatic venous pressure gradient 48 weeks after end of treatment; final results of the study of sofosbuvir plus ribavirin in patientswith cirrhosis and portal hypertension. J Hepatol. 2016;64:S221-S222.
37. Fontana RJ, Hann HWL, Perrillo RP, et al. Determinants of early mortality in patients with decompensated chronic hepatitis B treated with antiviral therapy. Gastroenterology. 2002;123:719-727.
38. Vanlemmens C, DiMartino V, MilanC, et al. Immediate listing for liver transplantation versus standard care for Child-Pugh stage b alcoholic cirrhosis: a randomized trial. Ann Intern Med. 2009;150:153-161.
39. Belli LS, Berenguer M, Cortesi PA, et al. Delisting of liver transplant candidates with chronic hepatitis C after viral eradication: a European study. J Hepatol. 2016;65:524-531.
40. Conti F, Buonfiglioli F, Scuteri A, et al. Early occurrence and recurrence of hepatocellular carcinoma in HCV-related cirrhosis treated with directacting antivirals. J Hepatol. 2016;65:727-733.
41. Reig M, Mariño Z, Perelló C, et al. Unexpected high rate of early tumor recurrence in patients with HCV-related HCC undergoing interferon-free therapy. J Hepatol. 2016;65:719-726.
42. ANRS Lack of evidence of an effect of direct-acting antivirals on the recurrence of hepatocellular carcinoma: data from three ANRS cohorts. J Hepatol. 2016;65:734-740.
43. Berenguer M, Prieto M, Rayón JM, et al. Natural history of clinically compensated hepatitis C virus-related graft cirrhosis after liver transplantation. Hepatology. 2000;32(4 Pt 1):852-858.
44. Biggins SW, Gralla J, Dodge JL, et al. Survival benefit of repeat liver transplantation in the United States: a serialMELD analysis by hepatitis C status and donor risk index. Am J Transplant. 2014;14:2588-2594.
45. Gane E. Abstracts of the 25th Annual Conference of APASL, February 20-24, 2016, Tokyo, Japan. Hepatol Int. 2016;10:1-506.
46. Forns X, CharltonM, Denning J, et al. Sofosbuvir compassionate use program for patients with severe recurrent hepatitis C after liver transplantation. Hepatology. 2015;61:1485-1494.
47. Wiesner RH, Sorrell M, Villamil F. Report of the first International Liver Transplantation Society expert panel consensus conference on liver transplantation and hepatitis C. Liver Transpl. 2003;9:S1-S119.
48. Narang TK, Ahrens W, Russo MW. Post-liver transplant cholestatic hepatitis C: a systematic review of clinical and pathological findings and application of consensus criteria. Liver Transplant. 2010;16:1228-1235.
49. Song AT, Sobesky R, Vinaixa C, et al. Predictive factors for survival and score application in liver retransplantation for hepatitis C recurrence.World J Gastroenterol. 2016;22:4547-4558.
50. Fontana RJ, Hughes EA, Bifano M, et al. Sofosbuvir and daclatasvir combination therapy in a liver transplant recipient with severe recurrent cholestatic hepatitis C. Am J Transplant. 2013;13:1601-1605.
51. Kim B, Trivedi A, Thung SN, et al. Case report of successful treatment of fibrosing cholestatic hepatitis c with sofosbuvir and ribavirin after liver transplantation. Semin Liver Dis. 2014;34:108-112.